title: Inhibition of neuroeffector transmission in human vas deferens by sildenafil.
abstract: Sildenafil (0.1 - 30 microM), a cyclic GMP phosphodiesterase 5 (PDE 5) inhibitor, induced inhibition of electrically evoked contractions of ring segments of human vas deferens from 34 vasectomies. Zaprinast (0.1 - 100 microM), another PDE 5 inhibitor, and the nitric oxide (NO) donor sodium nitroprusside (SNP) (0.1 - 100 microM) had no effect on neurogenic contractions. The inhibition induced by sildenafil was not modified by the inhibitor of guanylate cyclase 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one (ODQ) (1 - 30 microM) but it was abolished by the K(+) channel blockers tetraethylammonium (TEA, 1 mM), iberiotoxin (0.1 microM) and charybdotoxin (0.1 microM). Sildenafil, zaprinast and SNP did not affect the contractions induced by noradrenaline. SNP (10 microM) caused elevation of cyclic GMP levels that was potentiated by sildenafil (10 microM) and zaprinast (100 microM). ODQ (10 microM) inhibited the increase in cyclic GMP. Sildenafil inhibits adrenergic neurotransmission in human vas deferens. The inhibition is not related to accumulation of cyclic GMP but is probably due to activation of prejunctional large-conductance Ca(2+)-activated K(+) channels.
authors.affiliation: Department of Physiology, University of Valencia, 46010, Valencia, Spain. medinap@post.uv.es
authors.forename: P
authors.initials: P
authors.lastname: Medina
authors.forename: G
authors.initials: G
authors.lastname: Segarra
authors.forename: B
authors.initials: B
authors.lastname: Torondel
authors.forename: P
authors.initials: P
authors.lastname: Chuan
authors.forename: C
authors.initials: C
authors.lastname: Domenech
authors.forename: J M
authors.initials: JM
authors.lastname: Vila
authors.forename: S
authors.initials: S
authors.lastname: Lluch
mesh_terms: D000328:Adult; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009569:Nitric Oxide / Q000502:physiology; D009599:Nitroprusside / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism* / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011687:Purines; D011688:Purinones / Q000494:pharmacology; D000068677:Sildenafil Citrate; D013450:Sulfones; D009435:Synaptic Transmission / Q000187:drug effects*; D014649:Vas Deferens / Q000187:drug effects*
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D015221:Potassium Channels; D011687:Purines; D011688:Purinones; D013450:Sulfones; D009599:Nitroprusside; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; C011145:zaprinast; D006152:Cyclic GMP; D009638:Norepinephrine